Current treatment options for benign prostatic hyperplasia and their impact on sexual function.
Larson
Thayne R
TR
Mayo Clinic Scottsdale, Scottsdale, AZ 85258, USA.
D058891:5-alpha Reductase Inhibitors; D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use; D007172:Erectile Dysfunction / Q000139:chemically induced* / Q000209:etiology* / Q000628:therapy; D018120:Finasteride / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D017075:Laser Coagulation / Q000009:adverse effects / Q000379:methods; D008297:Male; D008875:Middle Aged; D019060:Minimally Invasive Surgical Procedures / Q000009:adverse effects / Q000379:methods; D011468:Prostatectomy / Q000009:adverse effects / Q000379:methods; D011470:Prostatic Hyperplasia / Q000188:drug therapy* / Q000601:surgery*; D011788:Quality of Life; D011799:Quinazolines / Q000627:therapeutic use; D012725:Sexual Behavior / Q000187:drug effects / Q000502:physiology*; D020728:Transurethral Resection of Prostate / Q000009:adverse effects / Q000379:methods
D058891:5-alpha Reductase Inhibitors; D000317:Adrenergic alpha-Antagonists; D011799:Quinazolines; D018120:Finasteride; C047638:alfuzosin